Mirati Therapeutics | MRTX - Passivo Circulante



Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Astellas Pharma JPY 1.32T 873M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bayer EUR 32.58B 3.63B 2025-12
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
J&J USD 54.13B 3.26B 2025-12
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Takeda JPY 2.61T 470.53B 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09